New hope for hard-to-treat ovarian cancer: experimental combo shows promise
NCT ID NCT07109414
First seen Nov 01, 2025 · Last updated May 16, 2026 · Updated 23 times
Summary
This study tests whether adding the experimental drug NP-G2-044 (Prilukae) to standard chemotherapy (PLD) can help people with platinum-resistant ovarian cancer, a type that has stopped responding to initial treatments. About 380 participants will receive either the combination or PLD alone. The goal is to see if the combo can shrink tumors or delay cancer growth, but it is not expected to be a cure.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PLATINUM-RESISTANT OVARIAN CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
HonorHealth Cancer Care
Phoenix, Arizona, 85016, United States
-
Optimum Clinical Research Group, LLC
Albuquerque, New Mexico, 87109, United States
-
Trials365
Shreveport, Louisiana, 71133, United States
-
University Of Wisconsin Carbone Cancer Center
Madison, Wisconsin, 53792-9988, United States
-
University of Pennsylvania Health System, Perelman Center for Advanced Medicine
Philadelphia, Pennsylvania, 19104-5127, United States
-
Utah Cancer Specialists
Salt Lake City, Utah, 84106, United States
Conditions
Explore the condition pages connected to this study.